Scientists from Tulane University and Shenzhen Third People's Hospital developed an improved CRISPR-Cas12a based tuberculosis test, ActCRISPR-TB, which offers rapid, sensitive detection without reliance on sputum samples. The single-tube assay uses recombinase polymerase amplification integrated with CRISPR detection, enabling results in under an hour with room temperature storage. This technology addresses diagnostic challenges in low-resource settings and could accelerate TB screening programs, helping to identify undiagnosed cases in symptomatic and asymptomatic individuals.